AND....Perhaps for the first time ever (?), we made an 'aural' abstract for this manuscript, with the help of Suno. /End
suno.com/song/67eb770e-…

🚨Out now in Blood Journal led by Tadeusz Kubicki
We studied blood mass spec (EXENT) as an MRD tool post-transplant in myeloma. What made this analysis unique is that IgG M-proteins persist after destruction of the culprit cells due to recycling /1 #mmMRD doi.org/10.1182/blood.…

Manni Mohyuddin Agree. Hope you can be there at my ASCO talk- I plan to focus mostly on what we have done and are doing in HCT to move the needle in disparities though I will start with 2-3 slides about current status of utilization and outcomes disparities…

Manni Mohyuddin I dont criticize you, Manni.
My point is just the opposite: let people do their work. Do not judge their intentions based on your assumptions.

There are good people running imperfect trials as much as there are good people writing DEI papers and not being able to fix the world.

Manni Mohyuddin Does that also applies for writing papers criticizing clinical trials and not conducting flawless clinical trials afterwards?

Manni Mohyuddin I beg to differ- you need to know the current status to assess the impact with efforts to mitigate the disparities !! So yes, intervention studies to address disparities are important but you cannot completely negate the value of descriptive studies!!

Liso-cel approved for Follicular Lymphoma! 🎉🎉🎉
Happy to have another CAR-T option for our patients!

fda.gov/drugs/resource…

Happy to see another #CARtcell option for our patients with #lymsm

Live at #SciMeeting24 : #BMT pioneer Dr. Rainer Storb receives a standing ovation at the conclusion of his keynote. The EBMT Fred Hutchinson Cancer Center

The legend Rainer Storb at #SciMeeting24 ASTCT The EBMT

You cannot but bowe to the achievements of the early transplanters and cellular therapists!

.Fred Hutchinson Cancer Center !

The legend himself! Prof. Rainer Storb tells the story of developing allo HCT #bmtsm from the very beginning. ⁦ASTCT⁩ ⁦The EBMT⁩ What a treat to get to hear this lecture.

UTSW Internal Medicine ⭐️⭐️⭐️⭐️⭐️ resident/ future hem ONC fellow (fellowships, she is great so keep her on your radar) Sharlene Dong killing it!

As always, Rahul Banerjee, MD, FACP Adeel Khan MD MPH MS & I are interested in what we say we do vs what we actually do when it comes to drug dosing.

Lei Deng, MD (He/Him) is a rising star focusing on lung cancer at Fred Hutchinson Cancer Center ! Always great to support junior faculty!
I was telling him about Bladder Cancer Advocacy Network walk on May 18!
Sarah P. Psutka MD MS Jessica Hawley MD MS OncoAlert Rafael Santana-Davila Suresh S. Ramalingam, MD, FASCO ECOG-ACRIN Cancer Research Group Rahul Banerjee, MD, FACP Heather Wakelee Dr. Tom Lynch

Dr. Simone Minnie Simone Minnie from Fred Hutchinson Cancer Center shares their findings that CD8 T cells, despite an exhausted phenotype, remain highly functional in hematologic tumors and are expanded by decoy-resistant IL-18 #immunotherapy . #IOTNCapstoneMeeting
Read More
pubmed.ncbi.nlm.nih.gov/38640253/

The #IMS24 abstract portal is open until May 30! 📆 📝 Don't miss your chance to submit your work. Learn more here: rb.gy/h7t32r📍 #myeloma #abstracts #submissiontime

Nursing & Allied Health #IMS2024 submit 👇👇🦜🦜see u there Monica Morris Beth Faiman PhD Tiffany Richards, PhD, ANP-BC, AOCNP Donna Catamero Andrea Preston Orla McCourt

CAR-T cells using murine scFv can be targeted by the patient’s immune system; Grauwet et al. (at Harvard) in J Immunother Cancer reveal how to combat this with “stealth transgenes” in the CAR-T cells that reduce their antigen and MHC expression. tinyurl.com/stealthCART

We are very pleased to participate in the Absolute Neutrophil Count (ANC) by Duffy Status Project.

It can be hard to talk to kids and grandkids about myeloma, but the IMF is here to help. Thanks to @Pfizer, the IMF's Care Partner Resource page can help you navigate your way: mmsm.link/3lQtJPO